Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1001-1020 of 2,120 trials

Crigler-Najjar Syndrome: GNT0003 Treatment Study

We are evaluating a new treatment called GNT0003 for adults with severe Crigler-Najjar syndrome who need daily phototherapy. The study aims to see if this treatment is safe and effective for those with pre-existing antibodies.

Crigler-Najjar Syndrome>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInternal Medicine

Advanced Solid Tumors and Blood Cancer: Durvalumab and Tremelimumab Study

We are testing the safety and early effectiveness of Durvalumab alone and with Tremelimumab in children with advanced solid tumors and blood cancers. This study aims to find the best dosage and understand how these treatments work.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Acute Myeloid Leukemia: Gemtuzumab Ozogamicin with Chemotherapy

We are studying whether adding gemtuzumab ozogamicin to standard chemotherapy helps reduce minimal residual disease in adults with newly diagnosed acute myeloid leukemia. This research aims to improve treatment outcomes and overall survival.

Favorable-Intermediate-Risk Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Septic Shock: Levetiracetam Treatment Study

We are studying whether early treatment with levetiracetam can help patients with septic shock stay awake and alert. The trial also examines its effects on survival and overall quality of life.

Septic Shock>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicineNeurologyPulmonology

Uncontrolled Asthma: Dupilumab vs. High Dose ICS

We are studying whether adding dupilumab to medium dose asthma medication helps reduce severe asthma attacks better than increasing the dose of current treatments. This trial is for adolescents and adults with uncontrolled asthma.

Asthma1-2 yearsMonitoring phase (IV)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyPulmonology

Meningococcal Disease: New Pentavalent Vaccine for Children

We are studying a new vaccine to see if it is safe and effective for healthy children, toddlers, and infants against meningococcal disease. The trial compares this vaccine with currently licensed options to evaluate immune responses.

Meningococcal Immunization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Pancreatic Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons better see pancreatic tumors during surgery. This study aims to improve the accuracy of tumor detection and assess the extent of cancer in patients who have received prior treatment.

Pancreatic Tumor3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Crohn's Disease: AZD7798 Treatment Study

We are investigating how well AZD7798 works and its safety for people with moderate to severe Crohn's disease. This study will help us understand its effects on disease activity and overall health.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Pancreatic Cancer: Organoid-Based Treatment Selection

We are studying whether lab-grown mini-tumors can help choose better post-surgery treatments for patients with resectable pancreatic cancer. This may improve recovery and outcomes after surgery.

Pancreatic Ductal Adenocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Interstitial Lung Disease: Rituximab and Mycophenolate Combination

We are studying a combination of rituximab and mycophenolate mofetil for patients with interstitial lung disease related to systemic sclerosis. The goal is to see if this treatment improves lung function and overall health compared to a placebo.

Lung Involvement in Systemic Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesPulmonologyRheumatology

Tau Imaging in Alzheimer's: Comparing PET Tracers

We are comparing three different PET tau tracers in volunteers to see which one best measures tau levels in the brain. This research may help improve diagnosis and treatment monitoring for Alzheimer's disease.

Cognitive Impairment>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Advanced Solid Tumors: DF6002 Treatment Study

We are investigating the safety and effectiveness of DF6002, alone and with Nivolumab, for patients with advanced solid tumors. This study aims to find the best dose and understand how well the treatment works.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesOncology

High-Risk Myelodysplastic Syndromes: Stem Cell Transplantation Study

We are evaluating a new treatment approach that combines hypomethylating therapy with stem cell transplantation for patients with high-risk myelodysplastic syndromes. The study aims to assess the feasibility and safety of this combined treatment.

Myelodysplastic SyndromeConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

B-Cell Acute Lymphoblastic Leukemia: Inotuzumab Ozogamicin Study

We are examining whether Inotuzumab can help adults with B-Cell Acute Lymphoblastic Leukemia achieve MRD negativity before stem cell transplantation. The study will also look at treatment safety and survival rates.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Targeted Anti-Cancer Treatment: ProTarget Trial

We are studying how effective and safe targeted cancer drugs are for patients with advanced cancer and specific genetic markers. This research may help improve treatment options based on individual genetic profiles.

Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Head and Neck Cancer: New Treatment Combinations

We are comparing a new drug combination with a single drug for patients with locally advanced head and neck cancer. The aim is to see which treatment works better before starting chemoradiotherapy.

Locally Advanced Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Vitamin C Treatment for Cardiac Surgery Patients

We are studying whether vitamin C can reduce inflammation and improve recovery in patients undergoing cardiac surgery. This trial compares vitamin C treatment to standard care to see which is more effective.

Cardiovascular Illness>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Advanced Solid Tumors: MOST Plus Treatment Study

We are studying a new maintenance treatment for patients with advanced solid tumors to see if it helps keep the disease stable after initial therapy. This trial compares ongoing treatment with stopping the therapy to understand the best approach.

Advanced or Metastatic Cancers>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Pancreatic Cancer: Personalized FOLFIRINOX Dosing Study

We are exploring how personalized dosing of the chemotherapy drug 5-FU affects safety and treatment outcomes in pancreatic cancer patients. This study aims to find the best dosing strategy to improve effectiveness and minimize side effects.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

High-Risk Medulloblastoma: New Treatment Approaches

We are exploring whether new radiotherapy and chemotherapy methods improve outcomes for children and adults with high-risk medulloblastoma. The study also looks at the long-term effects of these treatments on patients' health and quality of life.

Medulloblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics